Results 201 to 210 of about 392,253 (296)

Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. [PDF]

Pancreas
Zou S, Wen C, Li F, Jiang L, Tian Q, Chen H, Deng X, Peng C, Shen B, Zhan Q.   +9 more
europepmc   +1 more source

Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12‐Year Retrospective Cohort Study of 3487 Consecutive Patients

Annals of Gastroenterological Surgery, EarlyView.
In this retrospective cohort of 3487 patients with CRC, history of CCY was associated with significantly worse prognosis in patients with proximal CRC but not in those with distal CRC. This differential prognostic impact showed a statistically significant interaction between tumor location and history of CCY and remained robust after PSM.
Masashi Tsunematsu, Koichiro Haruki, Kazuhiro Yanamoto, Takuo Takehana, Shunta Ishizaki, Mitsuru Yanagaki, Yoshihiro Shirai, Kenei Furukawa, Shinji Onda, Toru Ikegami   +9 more
wiley   +1 more source

Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: where do we stand? [PDF]

BMJ Oncol
Yip PL, Lee SF, Chua M.
europepmc   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Survival outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer patients. [PDF]

Oncologist
Wang C, Zhang J, Chen J, Zhang X, Zhang S, Zhang P, Li J.   +6 more
europepmc   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Does different surgical approaches affect tolerance to postoperative adjuvant chemotherapy in early-stage upper gastric cancer? [PDF]

Front Surg
Zuo S, Zhang Y, Liao X.
europepmc   +1 more source

Effect of Broad‐Spectrum Antibiotic Prophylaxis on Post‐Pancreatoduodenectomy Infectious Complications: Nationwide Inpatient Database Study in Japan

Annals of Gastroenterological Surgery, EarlyView.
Using a nationwide Japanese inpatient database, we evaluated whether broad‐spectrum antibiotic prophylaxis improves postoperative outcomes after pancreatoduodenectomy compared with narrow‐spectrum antibiotics. In propensity score–weighted analyses of 45 099 patients, broad‐spectrum prophylaxis was associated with significantly lower rates of intra ...
Hiroki Kitagawa, Shotaro Aso, Yuki Hirano, Kenichiro Uemura, Keita Kouzu, Satoru Matsuda, Hiroki Matsui, Kiyohide Fushimi, Junichi Sasaki, Yuko Kitagawa, Hideo Yasunaga   +10 more
wiley   +1 more source

Correction: Evaluation of PINK1 protein expression as a predictive marker for the efficacy of adjuvant chemotherapy in colorectal cancer: a retrospective study. [PDF]

BMC Gastroenterol
Fujii T, Hirasaki M, Kamakura Y, Kawasaki T, Yamasaki S, Ishiyama Y, Hiranuma C, Hamaguchi T, Hirano Y, Sakuramoto S.   +9 more
europepmc   +1 more source

Management Strategies for Disappearing Colorectal Liver Metastases After Systemic Chemotherapy: Long‐Term Outcomes and Preoperative Prediction of ‘True Complete Response’

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma, Ryo Ashida, Takeshi Kawakami, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Yoshiyasu Kato, Kentaro Yamazaki, Katsuhiko Uesaka, Teiichi Sugiura   +9 more
wiley   +1 more source